Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences (Nasdaq: VTYX) will present at two upcoming investor conferences. The 5th Annual Evercore ISI HealthCONx Conference is on November 29, 2022, from 1:00-1:20 PM ET, virtually. The Piper Sandler 34th Annual Healthcare Conference is scheduled for December 1, 2022, at 9:30-9:55 AM ET in New York, NY. Management will also hold investor meetings. Webcasts of the presentations will be available on the Ventyx website, with replays accessible for 30 days.
- None.
- None.
ENCINITAS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences:
- Event: 5th Annual Evercore ISI HealthCONx Conference
Location: Virtual
Date: Tuesday, November 29, 2022
Time: 1:00-1:20 PM ET
- Event: Piper Sandler 34th Annual Healthcare Conference
Location: New York, NY
Date: Thursday, December 1, 2022
Time: 9:30-9:55 AM ET
Members of the Ventyx management team will also host investor meetings during the conferences.
Webcasts of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for thirty days.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three clinical-stage internally discovered programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
FAQ
What are the dates for Ventyx Biosciences' upcoming presentations?
Where can I watch the Ventyx Biosciences presentations?
What is the focus of Ventyx Biosciences?
What is the stock symbol for Ventyx Biosciences?
Who is speaking at the Ventyx investor conferences?
